LGND Q1 2018 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M+91.9% YoY

Gross Profit

$55M98.6% margin

Operating Income

$37M66.0% margin

Net Income

$45M80.6% margin

EPS (Diluted)

$1.83

QoQ Revenue Growth

+11.3%

Cash Flow

Operating Cash Flow

$61M

Free Cash Flow

$60M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$755M

Total Liabilities

$257M

Stockholders' Equity

$497M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$29M	+91.9%
Gross Profit	$55M	$29M	+91.4%
Operating Income	$37M	$10M	+262.6%
Net Income	$45M	$5M	+791.5%

Revenue Segments

License Fees, Milestones, and Product, Other

$31M29%

License Fees

$27M25%

Royalty

$21M19%

Royalty, Promacta

$16M14%

Material Sales, Captisol

$4M4%

Royalty, Kyprolis

$3M3%

Milestone

$3M3%

Royalty, Evomela

$2M1%

License Fees, Milestones, and Product, Other, Product, Other

$1M1%

Royalty, Product, Other

$400,0000%